Royalty Pharma plc (RPRX) Stock Price, Chart & Analysis
About Royalty Pharma plc (RPRX)
Healthcare · Biotechnology
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NMS
- CEO
- Mr. Pablo Legorreta
- Employees
- 100
- IPO year
- 2020
- Market cap
- $36.8B
- P/E (TTM)
- 33.87
- Forward P/E
- 10.96
- EPS (TTM)
- $1.88
- Book value
- $15.33
- Dividend yield
- 0.0147%
- 52-week range
- $35.92 – $64.38
- Beta
- 0.41
- Revenue (TTM)
- $2.5B
- Profit margin
- 32.0%
- Return on equity
- 14.0%